Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT.

Lucas GoenseJelle P RuurdaBrett W CarterPenny FangLinus HoGert J MeijerRichard van HillegersbergWayne L HofstetterSteven H Lin

Published in: European journal of nuclear medicine and molecular imaging (2018)

18F-FDG PET/CT restaging detects distant interval metastases in 8.3% of patients after chemoradiotherapy for oesophageal cancer. The provided prediction score may stratify risk of developing interval metastasis, and could be used to prioritize additional restaging modalities for patients most likely to benefit.

Keyphrases

end stage renal disease
rectal cancer
ejection fraction
newly diagnosed
chronic kidney disease
locally advanced
papillary thyroid
prognostic factors
patient reported outcomes
squamous cell
radiation therapy